{"id":531504,"date":"2021-02-24T06:58:01","date_gmt":"2021-02-24T06:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531504"},"modified":"2021-02-24T06:58:01","modified_gmt":"2021-02-24T06:58:01","slug":"porphyria-market-size-share-epidemiology-and-competitive-analysis-report-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/porphyria-market-size-share-epidemiology-and-competitive-analysis-report-2030-by-delveinsight_531504.html","title":{"rendered":"Porphyria Market Size, Share, Epidemiology and Competitive Analysis Report 2030 by DelveInsight"},"content":{"rendered":"
\"Porphyria<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Porphyria – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Porphyria, historical and forecasted epidemiology as well as the Porphyria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight launched a new report on Porphyria Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>.<\/p>\n

DelveInsight’s “Porphyria Market Report 2030<\/strong><\/a>” report delivers an in-depth understanding of the Porphyria, historical and forecasted epidemiology as well as the Porphyria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n

\"\"<\/p>\n

About Porphyria<\/strong><\/p>\n

A porphyria is a group of metabolic disorders caused by caused due to the accumulation of porphyrins or porphyrin precursors inside the body. It is not a single disease but a group of at least eight disorders that differ considerably from each other. Porphyrias are rare diseases and all forms of porphyria affect lesser than 200,000 people in the United States. In European countries, the most common porphyria is Porphyria Cutanea Tarda (PCT), affecting 1 in 10,000. Congenital erythropoietic porphyria (CEP) is extremely rare with prevalence estimates of 1 in 1,000,000 or less.<\/p>\n

Click here and request free sample pages of the report.<\/strong><\/a><\/p>\n

Porphyria Drug Therapy Assessment:<\/strong><\/p>\n

1. Normosang by Orphan-Europe<\/p>\n

2. Givosiran by Alnylam Pharmaceuticals<\/p>\n

“According to DelveInsight, the Porphyria prevalence<\/strong><\/a> in the age group of 40-70 for the United States is expected to vary from XXX million in 2015 to XXX million in 2025 at a CAGR of XX%.”<\/p>\n

Table of contents<\/strong><\/p>\n

1 Key Insights
2 Executive Summary of Porphyria
3 Porphyria Market Overview at a Glance
4 Disease Background and Overview: Porphyria
5 Case Reports
6 Porphyria Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Porphyria Treatment and Medical Practices
11 Unmet needs
12 Porphyria Marketed Drugs
13 Porphyria Emerging Drugs
14 Porphyria 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Porphyria Market Drivers
19 Porphyria Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

Download report: https:\/\/www.delveinsight.com\/report-store\/porphyria-market<\/span><\/a><\/strong><\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Porphyria – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Porphyria, historical and forecasted epidemiology as well as the Porphyria market trends in the United States, EU5 (Germany, Spain, Italy, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531504","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531504"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531504\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}